Special notice
notice of intent - Biotheranostics Inc.
HT0014biotheranostics
Defense Health Agency (Dha), Defense Health Agency. Analytical Laboratory Instrument Manufacturing.
Response deadline
September 16, 2024 at 9:00 AM EDT
Closed 776 days ago. Posted September 12, 2024. Scheduled to archive September 16, 2024.
Get the next one like this from Defense Health Agency (Dha) by email, the day it is posted.Find my opportunities
This one closed in 2024
39 like it are open now in analytical laboratory instrument manufacturing
- INFRARED TELESCOPE AND ACCESSORIES
Department of the Navy, Naval Research Laboratory
Combined synopsis and solicitationSmall businessNAICS 334516Anywhere in the USN00173-27-Q-1301397725Closes tomorrowNov 2 - Electrophoresis Testing for the Albany, Buffalo, and Syracuse VA Medical Centers
Department of Veterans Affairs, 242-Network Contract Office 02
Combined synopsis and solicitationNAICS 334516Anywhere in the US36C24226Q0949Closes tomorrowNov 2 - Vacuum Chamber
Department of Energy, ORNL Ut-Battelle LLC-DOE Contractor
Combined synopsis and solicitationNAICS 334516Anywhere in the USRFQ501580Closes tomorrowNov 2
All 39 open in analytical laboratory instrument manufacturing
Description
As published on SAM.gov.
The Defense Health Agency (DHA), Northeastern Markets Contracting Division (NM-CD), on behalf of Walter Reed National Military Medical Center (WRNMMC) intends to award a firm fixed price contract on a sole source basis to Biotheranostics Inc. (CAGE: 1FJJ9) The anticipated award will be made under the statutory authority permitting Other than Full and Open Competition pursuant to FAR 6.302-1 “Only one responsible source and no other supplies or services will satisfy agency requirements”.
The contract is intended to procure the breast cancer index that analyzes the activity of 11 genes to help predict the risk of early-stage, hormone-receptor-positive breast cancer coming back 5 to 10 years after diagnosis. These tests analyze a sample of a cancer tumor to see how active certain genes are. The activity level of these genes affects the behavior of the cancer, including how likely it is to grow and spread.
Genomic tests are used to help make decisions about whether more treatments after surgery would be beneficial. . Biotheranostics Inc is the only vendor that owns the proprietary copyrights of this testing. This notice of intent is NOT a request for competitive proposals or quotations. Requests for copies of a solicitation in response to this notice will not be honored or acknowledged. Phone calls will not be accepted.
A determination by the Government to not compete this proposed action based upon response to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether conducting a competitive procurement is in the best interest of the Government. Interested parties may identify their interest and capabilities by responding to this notice no later than 9am EST, Tuesday, September 12, 2024 by email to claudia.a.febresmormontoy.ctr@health.mil. All information submitted should support the offeror’s capability to provide the training required and shall be furnished at no cost or obligation to the Government.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
September 12, 2024
Special notice
Due September 16, 2024 at 9:00 AM EDT. SAM.gov, notice 3162135ff010430a8c468df7fadb3d11
Points of contact
- CLAUDIA FEBRES MORMONTOYclaudia.a.febresmormontoy.ctr@health.mil7032756342